Trial reportClinical psychology & psychotherapy
Culturally Adapted Manual-Assisted Psychological Intervention (CaMaPI) for Adolescents/Young People With a History of Self-Harm and Suicidal Ideation in Nigeria: A Randomised Controlled Feasibility Trial.
Trial report in Clinical psychology & psychotherapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06440031 (Culturally-adapted Manual-assisted Psychological Intervention), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Culturally-adapted Manual-assisted Psychological Intervention (CaMaPi) for Adolescents/Young People With a History of Self-harm and Suicidal Ideation in Jos, Nigeria
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundGlobally, suicide is the second leading cause of death for adolescents/young people aged 15-30-years old. The mainstream care for these affected persons is mostly unsuccessful due to limited culturally appropriate care.
methodsThis is a mixed-methods randomised controlled feasibility trial design. A culturally adapted manual-assisted psychological intervention (CaMaPI) was utilised to treat adolescents/young people with histories of self-harm and suicidal ideation. CaMaPI is a manualised intervention consisting of 10 sessions, grounded in psychoeducation and cognitive behavioural therapy. Participants aged 18-29 were screened for self-harm and suicidal ideation. N = 20 participants were randomised into CaMaPI (n = 10) or Treatment as Usual (TaU) (n = 10) groups. One focus group with n = 8 participants, and n = 3 individual interviews were conducted with the experimental group.
resultSatisfaction with intervention (CaMaPI, 100%; TaU, 50%). Reduction in self-harm and suicidal ideation was higher in CaMaPI on the suicide and self-harm scale at Md = 1.00 with z = -2.264, compared to TaU, Md = 3.00 with z = -0.378. Both groups showed no significant reduction in hopelessness. Emerging themes from the qualitative findings showed acceptance of self-harm and suicidal ideation as a treatable condition, mood management and behaviour modification, alongside cultural appropriateness and positive experience of the CaMaPI.
conclusionsCaMaPI is feasible, culturally appropriate and acceptable in reducing self-harm and suicidal ideation in adolescents/young people with histories of self-harm and suicidal ideation in Nigeria. A fully powered randomised control trial is recommended to evaluate the clinical and cost-effectiveness of CaMaPI compared with TAU.
trial registrationClinicalTrials.gov (No. NCT06440031) KEY PRACTITIONER MESSAGE: Suicide is one of the leading causes of death among 15- to 29-year-olds globally. Seventy-three percent of all suicides and self-harm happen in low- and middle-income countries, including Nigeria. CaMaPI is acceptable, culturally appropriate and feasible for treating suicidal ideation and self-harm behaviours in adolescents and young people. CaMaPI is manualised and delivered with minimal resources by trained clinical psychology researchers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.